Loading
Life sciences · Interventional Study
ClinicalTrials.gov · October 22, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Interventional Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07889570). This is a study registration, not published results. Lead sponsor: Evolv. Recruitment status: COMPLETED. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 98 participants (ACTUAL). Conditions: Overweight, Obesity, Blood Sugar Regulation, Appetite Suppression, Weight Management. Interventions: DIETARY_SUPPLEMENT: Evolv GLP-1 Group; OTHER: Control Group. Primary outcome measures: Change in Hemoglobin A1c (HgbA1c) , Baseline, Week 6, and Week 12; Change in Body Weight , Baseline, Week 4, Week 6, Week 8, and Week 12; Change in Waist Circumference , Baseline, Week 4, Week 6, Week 8, and Week 12. Brief summary: This is a randomized, controlled, hybrid clinical trial evaluating the effects of the Evolv GLP-1 supplement on weight loss, blood sugar regulation, and appetite suppression over 12 weeks. Participants are randomized to either the intervention group (8 capsules daily) or a control group receiving standardized healthy eating guidance from the American Diabetes Association. The study enrolls 98 male and female participants aged 18 and older with a BMI of 25-29.9 kg/m2. Primary endpoints include Hemoglobin A1c (HgbA1c) measured via bloodwork at Baseline, Week 6, and Week 12, as well as body weight and waist circumference measurements collected at Baseline, Week 4, Week 6, Week 8, and Week 12. Secondary endpoints capture participant perceptions of appetite suppression, weight loss, blood sugar, and overall well-being via self-reported questionnaires at the same time points.